{"entity":{"id":"nct03945721","kind":"trial","name":"Niraparib with postoperative radiotherapy in residual TNBC","aka":[],"tldr":"Niraparib is studied with radiation after breast surgery. The study is active but is not accepting new participants.","summary":"Registry status active not recruiting, last updated 2026-06-17. Enrollment is 21 actual. Residual non-metastatic TNBC after definitive surgery, with planned postoperative radiation. The registry requires residual invasive disease after neoadjuvant chemotherapy, or at least 1 cm for surgery-first patients, performance status and organ-function gates, and discontinuation of cytotoxic, immune and biologic treatment before RT. This phase 1 safety strategy does not establish recurrence prevention or current access.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT03945721","url":"https://clinicaltrials.gov/study/NCT03945721"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["niraparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03945721","phase":"1","setting":"Residual non-metastatic TNBC after definitive surgery, with planned postoperative radiation","sponsor":"Massachusetts General Hospital","started":"2019-07-11","startedType":"actual","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03945721/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"}]}}